...
首页> 外文期刊>Clinical cardiology. >Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo-A systematic review
【24h】

Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo-A systematic review

机译:质子泵抑制剂对氯吡格雷体内药效的药效学影响-系统评价

获取原文
获取原文并翻译 | 示例

摘要

Background: There is considerable debate about whether concomitant use of proton pump inhibitors (PPIs) should be recommended for patients who are prescribed clopidogrel after acute coronary syndrome. Most pharmacokinetic and pharmacodynamic studies in vivo were conducted using small sample sizes and were single centered, resulting in conflicting data. Hypothesis: PPIs may attenuate the antiplatelet effect of clopidogrel in vivo and lead to an increased risk of cardiovascular events. Methods: PubMed, the Cochrane Library, Embase, Web of Science, and China Biology Medicine Disc were searched. Randomized controlled trials that compared pharmacodynamic impacts of a PPI on the efficacy of clopidogrel in vivo were included. Two independent reviewers evaluated study quality and extracted data for meta-analysis. Results: We identified 8 eligible studies. Compared to clopidogrel treatment alone, patients who received both a PPI and clopidogrel had less of a decrease in the platelet reactivity index (weighted mean difference [WMD]: 8.18; 95% confidence interval [CI]: 6.81-9.56; P < 0.00001), less adenosine 5-diphosphate-induced platelet aggregation inhibition (WMD: 7.28; 95% CI: 2.44-12.11; P = 0.003), higher P2Y12 reaction units (WMD: 40.58; 95% CI: 19.31-61.86; P = 0.0002), and higher risks of clopidogrel resistance (odds ratio [OR]: 2.49; 95% CI: 1.49-4.14; P = 0.0005). There were no significant differences, however, for the incidences of major adverse cardiovascular events between the 2 groups (OR: 1.07; 95% CI: 0.44-2.59; P = 0.88), and treatment with a PPI and clopidogrel significantly reduced the risk of adverse gastrointestinal events (OR: 0.16; 95% CI: 0.04-0.62; P = 0.008). Conclusions: Concomitant use of a PPI with clopidogrel attenuated the antiplatelet effect of clopidogrel, but may be clinically unimportant because there were no clinical differences in the risk for major adverse cardiovascular events.
机译:背景:对于急性冠脉综合征后开具氯吡格雷处方的患者,是否应建议同时使用质子泵抑制剂(PPIs)存在很多争议。大多数体内药代动力学和药效学研究都是使用小样本量进行的,并且都是单中心的,从而导致数据矛盾。假设:PPI可能会减弱体内氯吡格雷的抗血小板作用,并导致心血管事件的风险增加。方法:检索PubMed,Cochrane图书馆,Embase,Web of Science和China Biology Medicine Disc。包括比较PPI对体内氯吡格雷功效的药效学影响的随机对照试验。两名独立评论者评估了研究质量并提取了数据进行荟萃分析。结果:我们确定了8项合格研究。与单独使用氯吡格雷治疗相比,同时接受PPI和氯吡格雷的患者的血小板反应性指数降低幅度较小(加权平均差异[WMD]:8.18; 95%置信区间[CI]:6.81-9.56; P <0.00001) ,较少的5-二磷酸腺苷诱导的血小板凝集抑制(WMD:7.28; 95%CI:2.44-12.11; P = 0.003),较高的P2Y12反应单位(WMD:40.58; 95%CI:19.31-61.86; P = 0.0002) ,氯吡格雷抵抗的风险更高(赔率[OR]:2.49; 95%CI:1.49-4.14; P = 0.0005)。但是,两组之间主要不良心血管事件的发生率没有显着差异(OR:1.07; 95%CI:0.44-2.59; P = 0.88),并且使用PPI和氯吡格雷治疗可显着降低患上心血管疾病的风险。胃肠道不良事件(OR:0.16; 95%CI:0.04-0.62; P = 0.008)。结论:PPI与氯吡格雷同时使用会减弱氯吡格雷的抗血小板作用,但可能在临床上并不重要,因为在重大不良心血管事件的风险上没有临床差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号